Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Liquidia stock price, quote, forecast and news

LQDA
US53635D2027
A2JRNS

Price

10.16
Today +/-
+1.14
Today %
+13.17 %
P

Liquidia stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Liquidia stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Liquidia stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Liquidia stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Liquidia's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Liquidia Stock Price History

DateLiquidia Price
9/11/202410.16 undefined
9/10/20248.90 undefined
9/9/20249.21 undefined
9/6/20249.10 undefined
9/5/20249.05 undefined
9/4/20248.94 undefined
9/3/20249.10 undefined
8/30/20249.51 undefined
8/29/20249.54 undefined
8/28/20249.54 undefined
8/27/20249.65 undefined
8/26/20249.83 undefined
8/23/20249.97 undefined
8/22/20249.63 undefined
8/21/20249.98 undefined
8/20/20249.60 undefined
8/19/20249.79 undefined
8/16/202414.11 undefined
8/15/202413.83 undefined
8/14/202413.74 undefined

Liquidia Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Liquidia, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Liquidia from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Liquidia’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Liquidia. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Liquidia’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Liquidia’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Liquidia’s growth potential.

Liquidia Revenue, EBIT and net profit per share

DateLiquidia RevenueLiquidia EBITLiquidia Net Income
2029e459.15 M undefined0 undefined78.33 M undefined
2028e357.24 M undefined143.97 M undefined14.88 M undefined
2027e324.62 M undefined123.58 M undefined-11.75 M undefined
2026e186.25 M undefined68.13 M undefined-16.24 M undefined
2025e52.75 M undefined-26.65 M undefined-131.69 M undefined
2024e15.76 M undefined-99.87 M undefined-132.43 M undefined
202317.49 M undefined-73.38 M undefined-78.5 M undefined
202215.94 M undefined-38.77 M undefined-41.02 M undefined
202112.85 M undefined-28.7 M undefined-34.58 M undefined
2020740,000 undefined-50.49 M undefined-59.76 M undefined
20198.07 M undefined-46.82 M undefined-47.58 M undefined
20182.71 M undefined-34.87 M undefined-53.14 M undefined
20177.26 M undefined-28.03 M undefined-29.15 M undefined
201613.22 M undefined-15.86 M undefined-15.93 M undefined

Liquidia Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
1372801215171552186324357459
--46.15-71.43300.00--25.0013.33-11.76246.67257.6974.1910.1928.57
92.3185.71100.0087.50-75.0086.6782.35------
12627091314000000
-15-28-34-46-50-28-38-73-99-26681231430
-115.38-400.00-1,700.00-575.00--233.33-253.33-429.41-660.00-50.0036.5637.9640.06-
-15-29-53-47-59-34-41-78-132-131-16-111478
-93.3382.76-11.3225.53-42.3720.5990.2469.23-0.76-87.79-31.25-227.27457.14
15.815.815.5618.4833.8949.6860.9664.99000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Liquidia Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Liquidia is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
1.43.439.555.865.357.593.383.68
1.11.60.300354.06
1000000000
00000000
0.50.40.20.60.80.81.52.16
3.15.44056.466.161.399.889.9
4.38.28.112.19.57.46.36.18
00000000
00000000
00005.54.43.73.43
00003.93.93.93.9
11.11.30.414.616.715.514.92
5.39.39.412.533.532.429.428.43
8.414.749.468.999.693.7129.2118.33
               
0000010010069
6679.7185.7250.2346374.8441476.32
-84.3-113.4-167.1-215.2-275-309.6-350.6-429.1
00000000
00000000
-18.3-33.718.6357165.390.547.29
2.44.43.23.53.71.12.21.4
2.96.146.55.35.96.414.43
3.63.90.301.8000
00000000
3.216.10.86.80.90.30.22.72
12.130.58.316.811.77.38.818.55
5.57.41211.310.510.820.143.48
00000000
9.210.610.55.76.210.49.99.01
14.71822.51716.721.23052.49
26.848.530.833.828.428.538.871.04
8.514.849.468.899.493.8129.3118.33
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Liquidia provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Liquidia's financial health and stability.

Assets

Liquidia's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Liquidia must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Liquidia after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Liquidia's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-15-29-53-47-59-34-41-78
00123532
00000000
000-6-1-12-25
142178142038
001,0000001,0000
00000000
-13-24-31-48-54-34-28-41
-2-20-1000-11
-2-20-1000-11
00001,000000
00000000
530-13-60817
00726371215525
628686663266443
0-1-20-1400
00000000
-10136169-735-9
-16.84-26.83-32.7-50.13-54.89-34.15-29.18-52.85
00000000

Liquidia stock margins

The Liquidia margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Liquidia. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Liquidia.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Liquidia's sales revenue. A higher gross margin percentage indicates that the Liquidia retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Liquidia's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Liquidia's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Liquidia's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Liquidia. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Liquidia's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Liquidia Margin History

Liquidia Gross marginLiquidia Profit marginLiquidia EBIT marginLiquidia Profit margin
2029e83.49 %0 %17.06 %
2028e83.49 %40.3 %4.17 %
2027e83.49 %38.07 %-3.62 %
2026e83.49 %36.58 %-8.72 %
2025e83.49 %-50.52 %-249.64 %
2024e83.49 %-633.59 %-840.13 %
202383.49 %-419.62 %-448.89 %
202282.06 %-243.22 %-257.34 %
202176.5 %-223.35 %-269.11 %
202067.57 %-6,822.97 %-8,075.67 %
201989.96 %-580.17 %-589.59 %
201895.57 %-1,286.72 %-1,960.89 %
201795.59 %-386.09 %-401.52 %
201693.04 %-119.97 %-120.5 %

Liquidia Stock Sales Revenue, EBIT, Earnings per Share

The Liquidia earnings per share therefore indicates how much revenue Liquidia has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Liquidia earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Liquidia's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Liquidia’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Liquidia's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Liquidia Revenue, EBIT and net profit per share

DateLiquidia Sales per ShareLiquidia EBIT per shareLiquidia Earnings per Share
2029e5.98 undefined0 undefined1.02 undefined
2028e4.65 undefined0 undefined0.19 undefined
2027e4.23 undefined0 undefined-0.15 undefined
2026e2.43 undefined0 undefined-0.21 undefined
2025e0.69 undefined0 undefined-1.71 undefined
2024e0.21 undefined0 undefined-1.72 undefined
20230.27 undefined-1.13 undefined-1.21 undefined
20220.26 undefined-0.64 undefined-0.67 undefined
20210.26 undefined-0.58 undefined-0.7 undefined
20200.02 undefined-1.49 undefined-1.76 undefined
20190.44 undefined-2.53 undefined-2.57 undefined
20180.17 undefined-2.24 undefined-3.42 undefined
20170.46 undefined-1.77 undefined-1.84 undefined
20160.84 undefined-1 undefined-1.01 undefined

Liquidia business model

Liquidia Corp is a biopharmaceutical company specializing in the development of novel therapeutic products using an advanced technology called Liqutex. This technology allows for precise control over the size, shape, and surface properties of particles, enabling targeted release of active ingredients in the body. The company was founded in 2004 as a spin-off from the University of North Carolina at Chapel Hill. It has been supported by prominent investors such as PPD, Inc. and New Enterprise Associates to advance the development of new drugs. Liquidia's business model is based on creating a comprehensive product portfolio with applications in various therapeutic areas, including immunology, oncology, infectious diseases, and pulmonary hypertension. The idea is to cover a wide range of applications with the Liqutex technology to increase competitiveness in the market. To achieve this, Liquidia has formed partnerships with other companies and research institutions to advance therapeutic development. For example, it collaborates with GlaxoSmithKline on the development of vaccines for pertussis and influenza. Another important aspect of Liquidia's business model is the creation of differentiated products that address a broader range of patient needs. For instance, the company has developed a novel drug combination for the treatment of pulmonary hypertension, which exhibits better efficacy and tolerability due to its specific formulation. In addition to its focus on therapeutic applications, Liquidia has also developed a range of products for industrial use. For example, it has a specialized technology for producing high-quality nanoparticles for the electronics industry. Overall, Liquidia stands out for its versatility and innovative solutions. The company has a unique technology platform that allows it to create differentiated products for both the medical and industrial sectors. Supported by an experienced management team and prominent investors, Liquidia is pursuing a holistic growth strategy to maintain a leading role in the biotechnology industry. Liquidia Corp is a biopharmaceutical company specializing in the development of novel therapeutic products using an advanced technology called Liqutex. The company was founded in 2004 as a spin-off from the University of North Carolina at Chapel Hill and has received support from investors such as PPD, Inc. and New Enterprise Associates. Liquidia's business model focuses on creating a comprehensive product portfolio with applications in various therapeutic areas, including immunology, oncology, infectious diseases, and pulmonary hypertension. The company aims to cover a wide range of applications with its Liqutex technology to increase competitiveness in the market. To achieve this, Liquidia has formed partnerships with other companies and research institutions, such as GlaxoSmithKline, to advance therapeutic development. Additionally, Liquidia prioritizes the creation of differentiated products that address a broader range of patient needs, such as a novel drug combination for the treatment of pulmonary hypertension. In addition to therapeutic applications, Liquidia has also developed products for industrial use, such as specialized technology for producing nanoparticles for the electronics industry. Liquidia distinguishes itself through its versatility and innovative solutions, with a unique technology platform and a holistic growth strategy supported by an experienced management team and prominent investors. Liquidia is one of the most popular companies on Eulerpool.com.

Liquidia SWOT Analysis

Strengths

Liquidia Corp has several key strengths that contribute to its success in the market:

The company excels in developing innovative technologies and solutions, giving it a competitive edge and allowing for differentiation in the market.

Liquidia Corp holds a robust portfolio of patents and intellectual property rights, providing protection for its innovations and creating barriers to entry for competitors.

The company's expertise in nanotechnology enables it to create advanced materials and delivery systems, opening up opportunities in various industries such as healthcare, electronics, and energy.

Weaknesses

Despite its strengths, Liquidia Corp also faces certain weaknesses that could hinder its growth and success:

The company's current product offerings are relatively limited, which may restrict its market reach and leave it vulnerable to competitors offering a wider range of solutions.

Liquidia Corp invests significant resources in research and development, which can strain its financials and hinder profitability, especially if new product launches do not meet expectations.

The company heavily relies on strategic partnerships for commercialization and distribution, making it vulnerable to the actions and decisions of its partners.

Opportunities

There are several opportunities in the market that Liquidia Corp can capitalize on:

The increasing need for high-performance materials across various industries presents an opportunity for Liquidia Corp to expand its customer base and revenue streams.

The healthcare sector is experiencing rapid growth, creating a favorable environment for Liquidia Corp to commercialize its innovative drug delivery systems and medical technologies.

The company can explore collaborations with industry leaders or research institutions to accelerate product development, enhance market reach, and strengthen its competitive position.

Threats

Several threats pose challenges to Liquidia Corp's growth and market position:

The market for advanced materials and nanotechnology is highly competitive, with new entrants and established players vying for market share, which may put pressure on Liquidia Corp's pricing and profitability.

As a result of operating in regulated industries such as healthcare, the company faces risks related to compliance with evolving regulations, potentially impacting product development and market access.

Unpredictable economic conditions, such as recessions or global financial crises, can impact customer demand, funding availability, and overall business performance for Liquidia Corp.

Liquidia Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Liquidia historical P/E ratio, EBIT, and P/S ratio.

Liquidia shares outstanding

The number of shares was Liquidia in 2023 — This indicates how many shares 64.993 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Liquidia earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Liquidia's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Liquidia’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Liquidia's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Liquidia.

Liquidia latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.35 -0.37  (-6.02 %)2024 Q2
3/31/2024-0.32 -0.54  (-66.67 %)2024 Q1
12/31/2023-0.24 -0.42  (-75.15 %)2023 Q4
9/30/2023-0.22 -0.24  (-9.89 %)2023 Q3
6/30/2023-0.17 -0.36  (-116.09 %)2023 Q2
3/31/2023-0.17 -0.18  (-8.76 %)2023 Q1
12/31/2022-0.16 -0.09  (43.07 %)2022 Q4
9/30/2022-0.17 -0.14  (18.56 %)2022 Q3
6/30/2022-0.23 -0.15  (35.51 %)2022 Q2
3/31/2022-0.21 -0.3  (-44.65 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Liquidia stock

Eulerpool World ESG Rating (EESG©)

49/ 100

🌱 Environment

54

👫 Social

49

🏛️ Governance

46

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Liquidia list of shareholders

%
Name
Stocks
Change
Date
7.56536 % Manning (Paul B.)5,809,440279,33012/31/2023
4.14722 % BlackRock Institutional Trust Company, N.A.3,184,651213,99912/31/2023
3.79889 % Canaan Partners2,917,1692,917,16912/31/2022
3.70351 % The Vanguard Group, Inc.2,843,92269,52412/31/2023
3.51390 % Kynam Capital Management LP2,698,324698,32412/31/2023
2.76357 % Jeffs (Roger A)2,122,143-8,3604/12/2024
2.71650 % Findell Capital Management LLC2,086,0002,086,00012/31/2023
13.49257 % Caligan Partners, LP10,360,9451,117,31812/31/2023
1.35813 % Geode Capital Management, L.L.C.1,042,90950,81012/31/2023
1.33481 % Vestal Point Capital, LP1,025,0001,025,00012/31/2023
1
2
3
4
5
...
10

Liquidia Executives and Management Board

Dr. Roger Jeffs61
Liquidia Chief Executive Officer, Director (since 2020)
Compensation 10.76 M
Mr. Michael Kaseta48
Liquidia Chief Financial Officer, Chief Operating Officer
Compensation 1.81 M
Mr. Russell Schundler48
Liquidia General Counsel, Secretary
Compensation 1.72 M
Dr. Stephen Bloch60
Liquidia Independent Chairman of the board
Compensation 153,874
Mr. Damian Degoa44
Liquidia Director (since 2020)
Compensation 153,119
1
2
3

Liquidia Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Aerie Pharmaceuticals Stock
Aerie Pharmaceuticals
SupplierCustomer0,83-0,200,58-0,23-0,84-0,54
Berry Global Group Stock
Berry Global Group
SupplierCustomer0,71-0,15-0,05-0,59-0,29-0,41
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,09-0,57-0,480,160,780,75
Lonza Group Stock
Lonza Group
SupplierCustomer-0,270,320,56-0,58-0,50-0,24
Novartis Stock
Novartis
SupplierCustomer-0,54-0,31-0,470,41-0,10-
1

Most common questions regarding Liquidia

What values and corporate philosophy does Liquidia represent?

Liquidia Corp represents values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on developing precision-engineered therapies, Liquidia's mission is to deliver transformative treatments to improve patients' lives. By leveraging their proprietary technology platform, PRINT®, Liquidia aims to address unmet medical needs and enhance therapeutic outcomes across various areas, including rare diseases and respiratory conditions. With a commitment to scientific excellence and a dedication to patient care, Liquidia Corp aims to set new standards in the field of biopharmaceuticals through cutting-edge research, strategic partnerships, and a patient-centered approach.

In which countries and regions is Liquidia primarily present?

Liquidia Corp is primarily present in the United States.

What significant milestones has the company Liquidia achieved?

Liquidia Corp has achieved several significant milestones since its inception. Notably, the company successfully completed its initial public offering (IPO) in July 2018, raising substantial funds to support its operations and future growth. Liquidia Corp also received FDA approval for its first product, LIQ861, in October 2019. This milestone marked a pivotal moment for the company, as LIQ861 is a potential breakthrough treatment for pulmonary arterial hypertension (PAH). Additionally, Liquidia Corp has established strategic partnerships and collaborations with renowned organizations, further enhancing its position in the biopharmaceutical industry. These achievements highlight the company's commitment to innovation and its potential for long-term success.

What is the history and background of the company Liquidia?

Liquidia Corp is a leading biopharmaceutical company specializing in the development of therapeutics using innovative particle engineering technology. Established in 2004, Liquidia has been focused on creating precision-engineered particles to enhance therapeutic outcomes. The company's proprietary PRINT® technology enables the design and production of precisely engineered particles with controllable size, shape, and composition. Liquidia develops a wide range of therapies for various diseases including respiratory conditions, such as pulmonary arterial hypertension (PAH). With a commitment to improving patient outcomes, Liquidia Corp continues to drive scientific innovation and advance the field of particle-based therapeutics.

Who are the main competitors of Liquidia in the market?

The main competitors of Liquidia Corp in the market are companies like Johnson & Johnson, Novartis, and Roche.

In which industries is Liquidia primarily active?

Liquidia Corp is primarily active in the pharmaceutical industry.

What is the business model of Liquidia?

The business model of Liquidia Corp revolves around the development and commercialization of novel products based on its versatile, proprietary PRINT® technology. The company utilizes its platform to design and manufacture precision-engineered particles and drug delivery systems for various therapeutic applications. Liquidia aims to address unmet medical needs by leveraging its expertise in materials science and engineering to enhance the efficacy and safety of pharmaceuticals. With a focus on partnerships and collaborations, Liquidia seeks to accelerate the development and commercialization of innovative therapeutics by leveraging the unique advantages of its PRINT® technology.

What is the P/E ratio of Liquidia 2024?

The Liquidia P/E ratio is -4.98.

What is the P/S ratio of Liquidia 2024?

The Liquidia P/S ratio is 41.87.

What is the AlleAktien quality score of Liquidia?

The AlleAktien quality score for Liquidia is 3/10.

What is the revenue of Liquidia 2024?

The expected Liquidia revenue is 15.76 M USD.

How high is the profit of Liquidia 2024?

The expected Liquidia profit is -132.43 M USD.

What is the business model of Liquidia

Liquidia Corp is a pharmaceutical company based in Research Triangle Park, North Carolina, specializing in the development and commercialization of novel therapeutics using its proprietary particle technology platform. The company has two core areas of focus: pulmonary hypertension therapy and nanoparticle technology. In the field of pulmonary hypertension therapy, Liquidia is developing a novel therapy that focuses on the use of surfactant, a natural lung surface protein, to improve respiratory function in patients with this condition. In 2018, Liquidia was granted Orphan Drug Designation by the US Department of Health, which emphasizes the development of drugs for rare diseases. In the area of nanoparticle technology, Liquidia produces customized nanoparticulate materials to optimize drug delivery and therapy. Liquidia's patented technology enables more effective and targeted delivery of medications, thereby increasing the effectiveness of therapeutics. This technology also allows for shorter drug development timelines and reduced production costs, further strengthening Liquidia's business model. Liquidia has built a network of business partners to increase awareness of its technology within the industry. A growing list of partners utilize the Liquidia platform to develop drugs in their portfolio. Additionally, Liquidia itself is expanding its product portfolio by applying its technology to new therapy areas. Overall, Liquidia has established a strong position as an innovative pharmaceutical company by bringing a unique technology platform to market. Liquidia is also a member and active partner in the global healthcare community, discussing the discovery, development, and commercialization of therapeutics. Liquidia's business model is centered around creating high value by offering unique solutions to the needs of patients and the industry through its technology platform. The product range and business relationships of Liquidia provide a solid foundation for expanding and increasing value for patients. Therefore, Liquidia Corp's business model is strengthened by its patented technology platform, enabling increased sales, accelerated development of therapeutics, and ultimately helping patients with serious conditions. As an expanding company with focus areas in various therapy fields, there are significant opportunities and challenges, but Liquidia's strategy of focusing on innovation and collaboration points in the right direction for continued success in this dynamic market.

What is the Liquidia dividend?

Liquidia pays a dividend of 0 USD distributed over payouts per year.

How often does Liquidia pay dividends?

The dividend cannot currently be calculated for Liquidia or the company does not pay out a dividend.

What is the Liquidia ISIN?

The ISIN of Liquidia is US53635D2027.

What is the Liquidia WKN?

The WKN of Liquidia is A2JRNS.

What is the Liquidia ticker?

The ticker of Liquidia is LQDA.

How much dividend does Liquidia pay?

Over the past 12 months, Liquidia paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Liquidia is expected to pay a dividend of 0 USD.

What is the dividend yield of Liquidia?

The current dividend yield of Liquidia is .

When does Liquidia pay dividends?

Liquidia pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Liquidia?

Liquidia paid dividends every year for the past 0 years.

What is the dividend of Liquidia?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Liquidia located?

Liquidia is assigned to the 'Health' sector.

Wann musste ich die Aktien von Liquidia kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Liquidia from 9/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did Liquidia pay the last dividend?

The last dividend was paid out on 9/12/2024.

What was the dividend of Liquidia in the year 2023?

In the year 2023, Liquidia distributed 0 USD as dividends.

In which currency does Liquidia pay out the dividend?

The dividends of Liquidia are distributed in USD.

All fundamentals about Liquidia

Our stock analysis for Liquidia Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Liquidia Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.